View Author
scopus: 35416436300

Kaspers, G.J.

(Gertjan Kaspers)


patient leukemia mutation myeloid leukemia study myeloid group blood expression children sample aberration cytogenetic analysis childhood treatment survival signi outcome cebpa table npm 1 mutations prognostic oncology cancer adult result number flt 3 relapse signi ficantly vegfc 3/itd wt 1 mutations difference figure erasmus mc factor diagnosis flt 3/itd probe evi 1 þ protocol netherland polymorphism cn-aml disease trial lymphoblastic leukemia abnormality event karyotype cohort fication mll-rearranged research subgroups chemotherapy erasmu mthfr value folate ficant level prognostic signi ficance effect ficantly wild-type probe sets 3-itd sensitivity mll-rearranged aml therapy university subtype subgroup frequency evi 1 flt 3-itd igsf 4 expression




10 Most Recent Publications

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: The impact of expensive chemotherapy (Article)
Tong, W.H. Sluis, I.M. van der Alleman, C.J.M. Litsenburg, R.R. van Kaspers, G.J. Pieters, R. Uyl-de Groot, C.A.
2013-05-01
Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia (Article)
Aalbers, A.M. Calado, R.T. Kaspers, G.J. Kuijpers, T.W. Reinhardt, D. Trka, J. Zimmermann, M. Pieters, R. Velden, V.H.J. van der Heuvel-Eibrink, M.M. van den Young, N.S. Zwaan, C.M. Wu, C. Kajigaya, S. Coenen, E.A. Baruchel, A. Geleijns, K. Haas, V. de
2013-02-21
Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: The influence of new medication and diagnostic technology (Article)
Litsenburg, R.R. van Uyl-de Groot, C.A. Raat, H. Kaspers, G.J. Gemke, R.J.
2011-12-01
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia (Article)
Balgobind, B.V. Hollink, I.H.I.M. Zemanová, Z. Stary, J. Cayuela, J.M. Baruchel, A. Creutzig, U. Reinhardt, D. Pieters, R. Michel Zwaan, C. Heuvel-Eibrink, M.M. van den Arentsen-Peters, S.T.C.J.M. Zimmermann, M. Harbott, J. Beverloo, H.B. Bergh, A.R.M. von Cloos, J. Kaspers, G.J. Haas, V. de
2011-10-01
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: Results of an international study (Article)
Coenen, E.A. Raimondi, S. Hasle, H. Harrison, C.J. Heerema, N.A. Kaspers, G.J. Leszl, A. Litvinko, N. Nigro, L.L. Morimoto, A. Perot, C. Auvrignon, A. Harbott, J. Reinhardt, D. Rubnitz, J.E. Smith, F.O. Stary, J. Stasevich, I. Strehl, S. Taga, T. Tomizawa, D. Webb, D. Zemanová, Z. Zimmermann, M. Alonzo, T.A. Pieters, R. Zwaan, C.M. Heuvel-Eibrink, M.M. van den Beverloo, H.B. Chang, M. Creutzig, U. Dworzak, M.N. Forestier, E. Gibson, B.
2011-06-30
Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia (Article)
Hollink, I.H.I.M. Heuvel-Eibrink, M.M. van den Trka, J. Baruchel, A. Creutzig, U. Pieters, R. Reinhardt, D. Zwaan, C.M. Arentsen-Peters, S.T.C.J.M. Zimmermann, M. Peeters, J. Valk, P.J.M. Balgobind, B.V. Sonneveld, E. Kaspers, G.J. Bont, E.S.J.M. de
2011-03-01
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia (Article)
Balgobind, B.V. Heuvel-Eibrink, M.M. van den Cayuela, J.M. Baruchel, A. Meyer, C. Marschalek, R. Trka, J. Stary, J. Beverloo, H.B. Pieters, R. Zwaan, C.M. Boer, M.L. den Menezes, R.X. de Reinhardt, D. Hollink, I.H.I.M. Arentsen-Peters, S.T.C.J.M. Wering, E.R. van Kaspers, G.J. Cloos, J. Bont, E.S.J.M. de
2011-02-01
High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23) (Article)
Kuipers, J.E. Coenen, E.A. Danen-van Oorschot, A.A. Boer, M.L. den Marschalek, R. Meyer, C. Pieters, R. Zwaan, C.M. Heuvel-Eibrink, M.M. van den Balgobind, B.V. Stary, J. Baruchel, A. Haas, V. de Bont, E.S.J.M. de Reinhardt, D. Kaspers, G.J. Cloos, J.
2011-01-20
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: Implications for personalized medicine (Article)
Bachas, C. Schuurhuis, G.J. Haas, V. de Assaraf, Y.G. Kaspers, G.J. Cloos, J. Hollink, I.H.I.M. Kwidama, Z.J. Goemans, B.F. Zwaan, C.M. Heuvel-Eibrink, M.M. van den Bont, E.S.J.M. de Reinhardt, D. Creutzig, U.
2010-10-14
FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657 (Article)
Goemans, B.F. Zwaan, C.M. Cloos, J. Lange, D. de Loonen, A.H. Reinhardt, D. Hählen, K. Gibson, B. Creutzig, U. Kaspers, G.J.
2010-10-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile